• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    10/31/24 4:17:57 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MNPR alert in real time by email
    SC 13G 1 tm2427181d1_sc13g.htm SC 13G

     

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Monopar Therapeutics Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    61023L207

    (CUSIP Number)

     

    October 24, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨     Rule 13d-1(b)

     

    x     Rule 13d-1(c)

     

    ¨     Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

     

     

     

    CUSIP No.   61023L207
     
    1

    Names of Reporting Persons

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF 

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    511,207

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    511,207

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    511,207

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.7%

     

    12

    Type of Reporting Person (See Instructions)

     

    IA, PN

     

           

     

     

     

    CUSIP No.   61023L207
     
    1

    Names of Reporting Persons

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United States

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    511,207

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    511,207

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    511,207

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.7%

     

    12

    Type of Reporting Person (See Instructions)

     

    HC, IN

     

           

     

     

     

    CUSIP No.   61023L207
     
    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United States

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH

     

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    511,207

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    511,207

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    511,207

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.7%

     

    12

    Type of Reporting Person (See Instructions)

     

    HC, IN

     

           

     

     

     

    CUSIP No.   61023L207
     
    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

     

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF 

    SHARES 

    BENEFICIALLY 

    OWNED BY 

    EACH 

    REPORTING 

    PERSON 

    WITH 

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    511,207

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    511,207

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    511,207

     

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.7%

     

    12

    Type of Reporting Person (See Instructions)

     

    PN

     

           

     

     

     

    Item 1(a). Name of Issuer:

     

    Monopar Therapeutics Inc. (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices:

     

    1000 Skokie Blvd., Suite 350, Wilmette, IL 60091

     

    Item 2(a). Names of Persons Filing:

     

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

    RA Capital Management, L.P. (“RA Capital”)

    Peter Kolchinsky

    Rajeev Shah

    RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:

     

    The address of the principal business office of each of the Reporting Persons is:

     

    c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c). Citizenship:

     

    RA Capital and the Fund are Delaware limited partnerships.

    Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d). Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (“Common Stock”)

     

    Item 2(e). CUSIP Number:

     

    61023L207

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 5,277,795 shares of Common Stock outstanding as of October 30, 2024 upon the closing of the Issuer’s public offering of Common Stock, as reported in the Issuer’s prospectus supplement dated October 28, 2024, filed with the Securities and Exchange Commission (the “SEC”) on October 29, 2024.

     

    The Fund directly holds 511,207 shares of Common Stock.

     

     

     

     

    RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (“Act”), of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the shares of the Issuer’s Common Stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act and therefore disclaims any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    Exhibit List

     

    Exhibit 1: Joint Filing Agreement

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: October 31, 2024

     

    RA CAPITAL MANAGEMENT, L.P.

     

    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  

     

     

    PETER KOLCHINSKY

     

    /s/ Peter Kolchinsky  

     

     

    RAJEEV SHAH

     

    /s/ Rajeev Shah  

     

     

    RA CAPITAL HEALTHCARE FUND, L.P.

     

    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
         
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

     

     

     

     

    Get the next $MNPR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MNPR

    DatePrice TargetRatingAnalyst
    9/9/2025$87.00Buy
    BTIG Research
    9/3/2025$77.00Outperform
    Oppenheimer
    9/3/2025$80.00Strong Buy
    Raymond James
    8/26/2025$70.00Buy
    H.C. Wainwright
    7/7/2025$74.00Overweight
    Cantor Fitzgerald
    6/23/2025$60.00Buy
    Chardan Capital Markets
    3/19/2025$76.00Overweight
    Piper Sandler
    1/10/2025$72.00Overweight
    Piper Sandler
    More analyst ratings

    $MNPR
    SEC Filings

    View All

    Monopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Monopar Therapeutics (0001645469) (Filer)

    9/15/25 7:00:11 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Monopar Therapeutics Inc.

    EFFECT - Monopar Therapeutics (0001645469) (Filer)

    9/10/25 12:15:22 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Monopar Therapeutics Inc.

    S-3 - Monopar Therapeutics (0001645469) (Filer)

    8/29/25 4:40:18 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tsuchimoto Kim R exercised 8,904 in-the-money shares at a strike of $0.01 and sold $356,171 worth of shares (8,904 units at $40.00) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/16/25 9:06:13 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Starr Christopher M exercised 16,800 in-the-money shares at a strike of $0.01 and sold $672,020 worth of shares (16,800 units at $40.00) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/16/25 9:03:50 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Robinson Chandler exercised 16,800 in-the-money shares at a strike of $0.01 and sold $672,020 worth of shares (16,800 units at $40.00) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    7/16/25 9:02:07 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

    WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th American Neurological Association (ANA) Annual Meeting on September 14-15, 2025. The poster and oral presentations will be delivered by Matthew Lorincz, M.D., Ph.D., Professor of Neurology and Co-Director of the Wilson Disease Center of Excellence at the University of

    9/14/25 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

    WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the long-term neurological benefits of ALXN1840 (tiomolybdate choline) in Wilson disease patients has been selected for both oral and poster presentations at the 150th American Neurological Association (ANA) Annual Meeting, to be held September 13-16, 2025, in Baltimore, Maryland. The abstract, titled "Long-term sustained improvement of neurological symptoms in Wilson disease patients on tiomolybdate choline,"

    9/3/25 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

    WILMETTE, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced second quarter 2025 financial results and recent developments. Recent Developments ALXN1840 for Wilson Disease On June 6, 2025, Alexion Pharmaceuticals officially transferred sponsorship of the investigational new drug ("IND") application for ALXN1840 to Monopar. The U.S. Food and Drug Administration ("FDA") acknowledged this change on July 29, 2025, confirming that the transfer was effective as of June 6, 2025. Monopar is now fu

    8/12/25 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Monopar Therapeutics with a new price target

    BTIG Research initiated coverage of Monopar Therapeutics with a rating of Buy and set a new price target of $87.00

    9/9/25 7:59:49 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Monopar Therapeutics with a new price target

    Oppenheimer initiated coverage of Monopar Therapeutics with a rating of Outperform and set a new price target of $77.00

    9/3/25 8:38:53 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Monopar Therapeutics with a new price target

    Raymond James initiated coverage of Monopar Therapeutics with a rating of Strong Buy and set a new price target of $80.00

    9/3/25 8:38:32 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    10/30/24 4:17:28 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    6/21/24 5:16:51 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    6/17/24 6:08:20 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Leadership Updates

    Live Leadership Updates

    View All

    Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

    Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease  NORTH CHICAGO, Ill., Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community. Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 t

    1/23/25 1:10:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Appoints Octávio Costa, MD, as Chief Medical Officer

    WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octávio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopar's pipeline. Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clini

    7/12/21 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics Expands Leadership Team with Appointment of Andrew Cittadine as Chief Operating Officer

    WILMETTE, Ill., June 01, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Andrew Cittadine, MBA, as Chief Operating Officer. In this role, Mr. Cittadine will provide leadership and oversight of Monopar's global operations and business and development strategy. Mr. Cittadine is an experienced healthcare executive and serial entrepreneur with a successful track record of identifying, founding, and building healthcare businesses from concept to commercialization

    6/1/21 4:05:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    SC 13G - Monopar Therapeutics (0001645469) (Subject)

    11/6/24 3:13:14 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Monopar Therapeutics Inc.

    SC 13G - Monopar Therapeutics (0001645469) (Subject)

    10/31/24 4:17:57 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MNPR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care